Cell-cell interactions in synovitis. Interactions between T lymphocytes and synovial cells

Arthritis Research

Volumn 2, Issue 5, 2000, Pages 374-378

  McInnes, I B ^a   Leung, B P ^a   Liew, F Y ^a  

^a GLASGOW ROYAL INFIRMARY   (United Kingdom)

Author keywords

Adhesion molecule; Cell contact; Cytokine; Rheumatoid arthritis; T lymphocyte

Indexed keywords

AUTOANTIGEN; BETA INTEGRIN; CYTOKINE; CYTOKINE RECEPTOR; INTEGRIN; INTERLEUKIN 10; INTERLEUKIN 11; INTERLEUKIN 15; INTERLEUKIN 17; INTERLEUKIN 18; INTERLEUKIN 1BETA; INTERLEUKIN 6; MATRIX METALLOPROTEINASE; PROSTAGLANDIN; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ANIMAL CELL; CELL ACTIVATION; CELL CONTACT; CELL INTERACTION; CELL MEMBRANE; CELL MIGRATION; CYTOKINE PRODUCTION; ENDOTHELIUM CELL; ENZYME SYNTHESIS; EXTRACELLULAR MATRIX; FEEDBACK SYSTEM; FIBROBLAST; HUMAN; HUMAN CELL; MACROPHAGE; NONHUMAN; REVIEW; RHEUMATOID ARTHRITIS; SYNOVIOCYTE; SYNOVITIS; T LYMPHOCYTE; TARGET CELL;

ANIMALS; ARTHRITIS, RHEUMATOID; CELL COMMUNICATION; HUMANS; SYNOVIAL MEMBRANE; SYNOVITIS; T-LYMPHOCYTES;

EID: 0034469236     PISSN: 14659905     EISSN: None     Source Type: Journal    
DOI: 10.1186/ar115     Document Type: Review

References (38)

1. Anti-cytokine therapy for rheumatoid arthritis
2. The role of T cells in the immunopathogenesis of rheumatoid arthritis: New perspectives
3. T-cell-dependent pathways in rheumatoid arthritis
4. Production of T-cell cytokines at the single-cell level in patients with inflammatory arthritides: Enhanced activity in synovial fluid compared to blood
5. Shift toward T lymphocytes with a T helper 1 cytokine-secretion profile in the joints of patients with rheumatoid arthritis
6. The chemokine receptors CXCR3 and CCR5 mark subsets of T cells associated with certain inflammatory reactions
7. High level of interleukin-10 production by the activated T cell population within the rheumatoid synovial membrane
8. Human interleukin-17: A T cell-derived proinflammatory cytokine produced by the rheumatoid synovium
9. High levels of IL-17 in rheumatoid arthritis patients: IL-15 triggers in vitro IL-17 production via cyclosporin A-sensitive mechanism
10. CCR5 is characteristic of Th1 lymphocytes
11. A proinflammatory role for IL-18 in rheumatoid arthritis
12. CD28 expression on T cell subsets in vivo and CD28-mediated T cell response in vitro in patients with rheumatoid arthritis
13. Central role of thrombospondin-1 in the activation and clonal expansion of inflammatory T cells
14. Expression and cleavage of tumor necrosis factor-alpha and tumor necrosis factor receptors by human monocytic cell lines upon direct contact with stimulated T cells
15. Cell surface glycoproteins expressed on activated human T cells induce production of interleukin-1 beta by monocytic cells: A possible role of CD69
16. Interleukin-15 mediates T cell-dependent regulation of tumor necrosis factor-alpha production in rheumatoid arthritis
17. Antigen-independent activation of naive and memory resting T cells by a cytokine combination
18. Cytokine stimulation of T lymphocytes regulates their capacity to induce monocyte production of tumor necrosis factor-alpha, but not interleukin-10: Possible relevance to pathophysiology of rheumatoid arthritis
19. Contact with T cells modulates monocyte IL-10 production: Role of T cell membrane TNF-alpha
20. IL-15 promotes IL-12 production by human monocytes via T cell-dependent contact and may contribute to IL-12-mediated IFN-gamma secretion by CD4+ T cells in the absence of TCR ligation
21. Human Th1 cells preferentially induce interleukin (IL)-1beta while Th2 cells induce IL-1 receptor antagonist production upon cell/cell contact with monocytes
22. CD40-CD40 ligand (CD154) engagement is required but may not be sufficient for human T helper 1 cell induction of interleukin-2 or interleukin-15-driven, contact-dependent, interleukin-1beta production by monocytes
23. Immobilized anti-CD3 antibody activates T cell clones to induce the production of interstitial collagenase, but not tissue inhibitor of metalloproteinases, in monocytic THP-1 cells and dermal fibroblasts
24. CD40 ligand-activated human monocytes amplify glomerular inflammatory responses through soluble and cell-to-cell contact-dependent mechanisms
25. Distinct T cell/renal tubular epithelial cell interactions define differential chemokine production: Implications for tubulointerstitial injury in chronic glomerulonephritides
26. Human monocytes constitutively express membrane-bound, biologically active, and interferon-gamma-upregulated interleukin-15
27. CD45-induced tumor necrosis factor alpha production in monocytes is phosphatidylinositol 3-kinase-dependent and nuclear factor-kappaB-independent
28. Effect of cytokine-induced soluble ICAM-1 from human synovial cells on synovial cell-lymphocyte adhesion
29. Direct contact between T lymphocytes and human dermal fibroblasts or synoviocytes down-regulates types I and III collagen production via cell-associated cytokines
30. Imbalance between interstitial collagenase and tissue inhibitor of metalloproteinases 1 in synoviocytes and fibroblasts upon direct contact with stimulated T lymphocytes: Involvement of membrane-associated cytokines
31. Production of interleukin-7 and interleukin-15 by fibroblast-like synoviocytes from patients with rheumatoid arthritis
32. T cell responses to a human cartillage autoantigen in the context of rheumatoid arthritis-associated and nonassociated HLA-DR4 alleles
33. T cell receptor repertoire in rheumatoid arthritis
34. Phenotypic characterization of CD4+ T cells that exhibit a transendothelial migratory capacity
35. Evidence for the continuous recruitment and activation of T cells into the joints of patients with rheumatoid arthritis
36. Interleukin 15 is produced by endothelial cells and increases the transendothelial migration of T cells in vitro and in the SCID mouse-human rheumatoid arthritis model in vivo
37. Production of cytokines and metalloproteinases in rheumatoid synovitis is T cell dependent
38. Percentage of anti-CD4 monoclonal antibody-coated lymphocytes in the rheumatoid joint is associated with clinical improvement. Implications for the development of immunotherapeutic dosing regimens